Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Mann

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Pharmaceutical Sciences|October 28, 2017
Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and CommercializationHaiyan Grady, David Elder, Gregory K Webster, et al.
JACC. Clinical Electrophysiology|June 1, 2022
Limitations of Unipolar Signals in Guiding Successful Outflow Tract Premature Ventricular Contraction AblationSyed Rafay Ali Sabzwari, Michael A Rosenberg, James Mann, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 4, 2019
Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitationPhilippe Berben, Lee Ashworth, Stefania Beato, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 31, 2013
In vitro models for the prediction of in vivo performance of oral dosage formsEdmund S Kostewicz, Bertil Abrahamsson, Marcus Brewster, et al.
Molecular Pharmaceutics|July 25, 2017
Validation of Dissolution Testing with Biorelevant Media: An OrBiTo StudyJames Mann, Jennifer Dressman, Karin Rosenblatt, et al.
Clinical Pharmacology in Drug Development|August 27, 2022
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump InhibitorsShringi Sharma, Xavier Pepin, Harini Burri, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 24, 2018
In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaborationJames Butler, Bart Hens, Maria Vertzoni, et al.
JAMA Oncology|February 2, 2023
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated CardiotoxicityBenjamin Buck, Aaron P Chum, Mitkumar Patel, et al.
Nature Communications|January 2, 2025
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseBrandon Zimmerman, Leslie A Dakin, Anne Fortier, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Pharmaceutical Sciences|October 28, 2017
Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and CommercializationHaiyan Grady, David Elder, Gregory K Webster, et al.
JACC. Clinical Electrophysiology|June 1, 2022
Limitations of Unipolar Signals in Guiding Successful Outflow Tract Premature Ventricular Contraction AblationSyed Rafay Ali Sabzwari, Michael A Rosenberg, James Mann, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 4, 2019
Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitationPhilippe Berben, Lee Ashworth, Stefania Beato, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 31, 2013
In vitro models for the prediction of in vivo performance of oral dosage formsEdmund S Kostewicz, Bertil Abrahamsson, Marcus Brewster, et al.
Molecular Pharmaceutics|July 25, 2017
Validation of Dissolution Testing with Biorelevant Media: An OrBiTo StudyJames Mann, Jennifer Dressman, Karin Rosenblatt, et al.
Clinical Pharmacology in Drug Development|August 27, 2022
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump InhibitorsShringi Sharma, Xavier Pepin, Harini Burri, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 24, 2018
In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaborationJames Butler, Bart Hens, Maria Vertzoni, et al.
JAMA Oncology|February 2, 2023
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated CardiotoxicityBenjamin Buck, Aaron P Chum, Mitkumar Patel, et al.
Nature Communications|January 2, 2025
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseBrandon Zimmerman, Leslie A Dakin, Anne Fortier, et al.
Pageof 4